# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K071255   
B. Purpose for Submission: clearance of a new device   
C. Measurand: IgG, IgA, and IgM heparin-dependent antibodies   
D. Type of Test: Enzyme linked immunosorbent assay   
E. Applicant: Hyphen BioMed F. Proprietary and Established Names: ZYMUTEST HIA IgG ZYMUTEST HIA IgGAM   
G. Regulatory Information:

1. Regulation section:

21 CFR 864.7695

2. Classification:

Class II

3. Product code:

LCO

4. Panel: 81 Hematology

# H. Intended Use:

# 1. Intended use(s):

The ZYMUTEST HIA IgGAM ELISA is a qualitative screening assay intended for the global detection of heparin-dependent antibodies, whether the isotype is: $\mathrm { I g G I g M }$ , and IgA, in human plasma, by clinical laboratories. It is intended for in vitro diagnostic use.

The ZYMUTEST HIA IgG ELISA is a qualitative assay intended for the detection of heparin-dependent antibodies of the IgG isotope, in human plasma, by clinical laboratories. It is intended for in vitro diagnostic use.

# 2. Indication(s) for use:

ZYMYUTEST HIA IgG AND IgGAM KITS are designed as a solid phase enzymelinked immunosorbent assay (ELISA). These products are intended to be used as an in vitro diagnostics kit by Hematology, coagulation or other pathology laboratories to assist in screening patient samples for the presence of heparin-associated antibodies commonly found in patients with heparin induced thrombocytopenia or thrombosis (HIT).

3. Special conditions for use statement(s):

4. Special instrument requirements:

# I. Device Description:

The assay kit consists of a 96 welled micro ELISA plate coated with unfractionated heparin, 3 vials each of lyophilized Positive and Negative controls, 3 vials lyophilized Platelet lysate, 3 vials of Immunoconjugate, $2 5 ~ \mathrm { m L }$ of TMB substrate, 1 vial of sulfuric Acid Stop solution, buffer, diluents, and wash solution.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

# 1. DIAGNOSTICA STAGO ASSERCHROM $\textsuperscript { \textregistered }$ HPIA TEST KIT

# 2. GTI PF4 ENHANCED SOLID PHASE ELISA

2. Predicate 510(k) number(s):

1. K003767   
2. K053559

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>A qualitative in vitrodiagnostic screeningassay intended for theglobal detection of IgG,IgM, and IgA heparin-dependent antibodies inhuman plasma, byclinical laboratories.</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>test principle</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>sample requirements</td><td rowspan=1 colspan=1>citrated plasma</td><td rowspan=1 colspan=1>same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>materials</td><td rowspan=1 colspan=1>Microtiter plate coatedwith unfractionatedheparin</td><td rowspan=1 colspan=1>microtiter plate coatedwith purified PF4complexed to polyvinlysulfonate</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

# L. Test Principle:

When a diluted plasma sample and platelet lysate is added to one of the microwells of the coated plate, if present, heparin-dependent antibodies present in the sample will form complexes with unfractionated heparin immobilized on the plate. Following a washing step, bound antibodies are mixed with the immunoconjuuagate, which will bind to $\mathrm { I g G }$ , IgM, and IgA isotypes. Following another washing step, the TMB peroxidase substrate is added, and a blue color develops which turns yellow upon the addition of the stop

solution. The color that develops is directly proportional to the amount of heparindependent antibodies present in the tested sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Intra-assay- ZYMUTEST HIA IgG and ZYMUTEST HIA IgGAM were tested in duplicate using positive control material.

<table><tr><td rowspan=1 colspan=1>Positive control</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean A450</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgG Lot 061027D</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>3.07</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgG Lot 061214A</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>4.46</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgGAM Lot 061214D</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>4.75</td></tr></table>

Inter-assay

<table><tr><td rowspan=1 colspan=1>Positive control</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean A450</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgG Lot 061027D</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1.34</td><td rowspan=1 colspan=1>7.11</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgGAM Lot 061027G</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>7.50</td></tr></table>

b. Linearity/assay reportable range:

n/a

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Negative controls are derived from normal human plasma with an A450 of mean $\pm 2$ SD.

The positive control is derived from chimeras made by coupling anti-PF4 polyclonal antibodies with human Igs (IgG, IgA or IGM, or the mixture of the three), with an A450 of mean $\pm 5$ SD.

d. Detection limit: n/a

e. Analytical specificity: The effect of varying concentrations of heparin in the assay was tested on 3 pathological plasmas with and without heparin addition,

ranging from 0 to $5 \mathrm { I U } / \mathrm { m l }$ . After heparin addition, plasma was diluted 1:100 and tested. Results demonstrated no heparin interference up to $1 \ : \mathrm { I U / m l }$ .

# f. Assay cut-off:

The assay was evaluated in hospital patients with no HIT, ACC patients with circulating anticoagulant antibodies with no HIT, and normal healthy donors with no autoimmunity background. Cut-off was established as mean $+ \ 3 { \bf S D }$ for the normal hospital patients and ACC patients, which corresponded to $+ 5$ SD for normal healthy donors.

2. Comparison studies:

a. Method comparison with predicate device:

ZYMUTEST IgGAM compared with Asserachrom. $\mathrm { N } { = } 4 4$ .

<table><tr><td rowspan=1 colspan=1>In-house Study</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Asserachrom</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ZymutestIgGAM</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=2>Agreement</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>88%</td></tr></table>

2 site clinical study ZYMUTEST IgGAM compared with Asserachrom

<table><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Asserachrom</td></tr><tr><td rowspan=1 colspan=1>Site 1 &amp; 2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ZymutestIgGAM</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>136</td></tr><tr><td rowspan=1 colspan=2>Agreement</td><td rowspan=1 colspan=1>76%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-positivity</td><td rowspan=1 colspan=1>64%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-negativity</td><td rowspan=1 colspan=1>81%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Sample Size</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1></td></tr></table>

3 site clinical study ZYMUTEST IgGAM compared with GTI PF4 Enhanced

<table><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>GTI PF4-Enhanced</td></tr><tr><td rowspan=1 colspan=1>Site 1, 2, &amp;3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ZymutestIgGAM</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>153</td></tr><tr><td rowspan=1 colspan=2>Agreement</td><td rowspan=1 colspan=1>74%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-positivity</td><td rowspan=1 colspan=1>58%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-negativity</td><td rowspan=1 colspan=1>90%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Sample Size</td><td rowspan=1 colspan=1>345</td><td rowspan=1 colspan=1></td></tr></table>

2 site clinical study- ZYMUTEST IgG compared with Asserachrom

<table><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Asserachrom</td></tr><tr><td rowspan=1 colspan=1>Site 1 &amp; 2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ZymutestIgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>151</td></tr><tr><td rowspan=1 colspan=2>Agreement</td><td rowspan=1 colspan=1>76%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-positivity</td><td rowspan=1 colspan=1>44%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-negativity</td><td rowspan=1 colspan=1>90%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Sample Size</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1></td></tr></table>

ZYMUTEST IgG compared with Serotonin Release Assay (SRA) $\mathrm { n } { = } 1 7 4$

<table><tr><td># Matches</td><td>131</td></tr><tr><td>% Matching</td><td>75.3%</td></tr></table>

b. Matrix comparison: n/a

3. Clinical studies: a. Clinical Sensitivity: n/a b. Clinical specificity: n/a c. Other clinical supportive data (when a. and b. are not applicable): n/a

4. Clinical cut-off: n/a

5. Expected values/Reference range: n/a

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.